Plasma Fractionation Market

According to Stratistics MRC, the Global Plasma Fractionation Market is accounted for $29.0 billion in 2023 and is expected to reach $46.2 billion by 2030 growing at a CAGR of 6.9% during the forecast period. In order to create therapeutic products that can be utilized to treat a variety of medical diseases, blood plasma's constituent parts are separated through a procedure called plasma fractionation. The liquid portion of blood, known as blood plasma, includes proteins and other materials necessary for body operations. These proteins are separated and purified for use in medicine using plasma fractionation. A vital procedure that offers treatments that can save lives for a variety of illnesses is plasma fractionation. Nonetheless, to guarantee that the finished goods are risk-free, efficient, and devoid of impurities, stringent adherence to quality and safety requirements is necessary.

According to a research study published by Springer in January 2022, Acquired hemophilia A (AHA) is a severe acquired rare bleeding disorder with which only 1-1.5 per million persons are affected yearly.  

Market Dynamics: 

Driver: 

Increasing numbers of immunodeficiency disorders

Worldwide, there has been a noticeable increase in the demand for treatments produced from plasma. Strong demand for immunoglobulin contributed to the global market's good expansion. The increase in different immunodeficiency diseases instances worldwide is the cause of the increased demand. Immunoglobulin replacement or targeted immunoglobulin therapy are two possible treatments for these illnesses. Consequently, as the need for these therapies grows, so does the amount of immunoglobulin produced by these methods, which propels the market.

Restraint:

Emergence of gene-editing therapies

By specifically targeting genetic defects, gene-editing therapies provide novel approaches to treating diseases and may eventually eliminate the need for some plasma-derived therapies. The use of gene-editing therapies may lead to a drop in the market share and income for plasma fractionation companies as a result of a decrease in the demand for products produced from plasma. Businesses that depend significantly on plasma-derived treatments may face financial consequences in the event that treatment paradigms significantly shift in favour of gene editing thereby hampering the market.

Opportunity:

Rise in plasma collection facilities across the globe

An increased supply of plasma as the raw material for plasma fractionation could result from more collection facilities. This increase in plasma availability may have a beneficial effect on the ability to produce products derived from plasma, such as albumin, clotting factors, and immunoglobulins. The market for plasma fractionation may be impacted by the location and legal framework of plasma collection facilities. Moreover, regulations pertaining to safety requirements, plasma collection, and the import and export of goods obtained from plasma vary throughout nations. 

Threat:

Technological challenges 

Problems with technology, like antiquated or ineffective plasma fractionation methods, can cause processing times to increase and productivity to decrease. Lower yields of plasma-derived products could be the consequence of this inefficiency, which would restrict the amount available for distribution and possibly raise expenses. Scalability issues may arise with some outdated technology or processes, making it challenging to raise output levels to keep up with demand. Inadequate scalability can impede the growth of markets and cause shortages in supplies.

Covid-19 Impact

The demand for goods produced from plasma, especially immunoglobulins, surged as a result of COVID-19. For COVID-19 patients who are extremely sick, these antibodies were investigated as a possible therapy option. As a result, there was an increase in the need for plasma from COVID-19 survivors in order to create convalescent plasma and maybe create treatments involving hyper immune globulin. To handle issues brought on by the pandemic, regulatory bodies modified their rules and regulations, guaranteeing the security and availability of goods obtained from plasma. 

The immunoglobulins segment is expected to be the largest during the forecast period

The immunoglobulins segment is estimated to have a lucrative growth, as immunoglobulins are used to treat a range of illnesses, such as immune deficiencies, autoimmune disorders, and several neurological ailments. Intravenous immunoglobulin (IVIG) is a widely used substance that is derived from plasma fractionation and is used to treat a variety of illnesses and strengthen the immune system.  The effectiveness of isolating immunoglobulins and other plasma proteins has been enhanced by ongoing technological improvements in plasma fractionation procedures, improving product yields and quality.

The depth filtration segment is expected to have the highest CAGR during the forecast period

The depth filtration segment is anticipated to witness the highest CAGR growth during the forecast period, because depth filtration is a crucial step in the purification and separation of proteins, including immunoglobulins and other vital constituents. It is used as one of the main techniques to get high-purity protein products by eliminating contaminants. In order to capture and hold particles of different sizes and separate them from the required components according to their size, shape, and interaction with the filter material, this procedure depends on the depth of the filter matrix thus boosting the market.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period, owing to the presence of governmental authorities that oversee and control plasma collection, fractionation, and sales is a major element driving the market's growth, and as a result, Asia-Pacific offers important participants in the plasma fractionation industry lucrative potential. Furthermore, a sharp increase in the emphasis of top producers on regional expansion in developing Asia-Pacific nations in order to gain a larger market share is anticipated to propel the growth of the plasma fractionation industry.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the presence of key companies, growing research and development efforts related to plasma fractionation, and an aging population, the North American region is anticipated to occupy a sizable proportion of the market for plasma fractionation.  Furthermore, the expansion of plasma collecting facilities in the area as well as ongoing initiatives to increase the availability of plasma is anticipated to fuel market expansion. For example, in order to increase Canada's national blood plasma supply, Grifols SA and Canadian Blood Services (CBS) joined in September 2022.  Thus the growing geriatric population, rising healthcare spending, and rising initiatives from key market are propelling the market growth.

Key players in the market

Some of the key players profiled in the Plasma Fractionation Market include Grifols, S.A., Intas Pharmaceuticals Ltd., LFB, Takeda Pharmaceutical company limited, Octapharma AG, Sanquin, Emergent BioSolutions, Shanghai Raas Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Kamada, Centurion Pharma, Virchow Biotech Private Limited, Fusion Healthcare, Hemarus Therapeutics Limited, Hualan Bioengineering Co., Ltd., China Biologic Products Holdings Inc., ADMA Biologics, CSL, Baxter International Inc and Bio Products Laboratory

Key Developments:

In December 2023, Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate. This current version of Emergent’s universal influenza vaccine candidate contains multiple components intended to induce broad.

In October 2023, Baxter Launches Digital Image Capture Capability for PanOptic Plus Ophthalmoscope, the iExaminer Pro System adds a key technology to routine eye exams, designed.

In July 2023, Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S. The Company Generated Approximately $16 Million in Revenue from Sales of KEDRAB to Kedrion in 2022 and Anticipates a Significant Increase in 2023

Products Covered:
• Immunoglobulins
• Albumin
• Platelets & Coagulation Factor Concentrates
• Protease Inhibitors
• Other Products
         
Methods Covered:
• Depth Filtration
• Chromatography
• Centrifugation

Applications Covered:
• Immunology
• Neurology
• Critical Care
• Hematology
• Rheumatology
• Hemato-Oncology
• Pulmonology
• Other Applications

End Users Covered:
• Clinical Research Laboratories
• Hospitals & Clinics
• Academic Institutes
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances